Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 Trial

Researchers in Australia have achieved a breakthrough in skin cancer treatment with a personalized mRNA cancer vaccine, SSBCrack reported. The Phase 3 clinical trial demonstrated a 42 percent reduction in the risk of melanoma recurrence or death. Medical oncologist Georgina Long, serving as global principal investigator from Melanoma Institute Australia, presented the findings at the European Society for Medical Oncology. [1]

As HEROIC BREAKING NEWS reported earlier, Professor Georgina Long led the phase three trial combining the personalized mRNA vaccine with a post-surgery immunotherapy drug to lower recurrence and mortality rates. The treatment works by targeting unique skin cancer mutations. The vaccine is expected to gain regulatory approval in the United States, Europe, and the United Kingdom next year. [5][6]

The development follows previous Australian advances in public health, including pioneering work on the HPV vaccine that has positioned the nation to potentially eliminate cervical cancer, SSBCrack reported. Background details show that specialized therapies like Intismeran autogene use automated algorithms and tissue sequencing to generate tailored mRNA sequences for cancer patients. [1][4]